Eupraxia Pharmaceuticals Inc. Common Stock vs. NVIDIA Corporation
EPRX
Eupraxia Pharmaceuticals Inc. Common Stock
$8.40 +12.00%
VS NVDANVIDIA Corporation
$230.36 +0.84%
Eupraxia Pharmaceuticals Inc. Common Stock and NVIDIA Corporation are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| EPRX | NVDA | |
|---|---|---|
| Market Cap | $555.02 million | $5.56 trillion |
| Revenue (TTM) | — | $302.97 billion |
| Net Income (TTM) | — | $192.88 billion |
NVDA leads on 1 of 1 size & scale factors.
Valuation
| EPRX | NVDA | |
|---|---|---|
| P/E Ratio | — | 29.12 |
| Price / Book | — | 24.29 |
| Price / Sales | — | 18.36 |
EPRX and NVDA split the valuation factors evenly.
Profitability
| EPRX | NVDA | |
|---|---|---|
| Net Margin | — | 63.66% |
| Return on Equity | — | 84.23% |
EPRX and NVDA split the profitability factors evenly.
Dividend
| EPRX | NVDA | |
|---|---|---|
| Dividend Yield | — | 0.43% |
| Payout Ratio | — | 12.64 |
EPRX and NVDA split the dividend factors evenly.
Risk & Sentiment
| EPRX | NVDA | |
|---|---|---|
| Short Interest | 0.01% | 0.07% |
EPRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: EPRX overview, EPRX financials, NVDA overview, NVDA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.